NASDAQ: HRTXHeron Therapeutics Inc Stock Ownership - Who owns Heron Therapeutics?
Insider buying vs selling
Have Heron Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Adam Morgan | Director | 2025-08-08 | 1,766,546 | $1.50 | $2.65MBuy |
| Rubric Capital Management LP | 10% Owner | 2025-08-08 | 2,387,225 | $1.50 | $3.58MBuy |
HRTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when HRTX insiders and whales buy or sell their stock.
HRTX Shareholders
What type of owners hold Heron Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Spch LLC | 25.02% | 38,174,476 | $47.34M | Insider |
| Rubric Capital Management LP | 19.07% | 29,100,728 | $36.08M | Insider |
| Rubric Capital Management LP | 17.51% | 26,713,503 | $33.12M | Institution |
| Perceptive Advisors LLC | 17.48% | 26,666,667 | $33.07M | Insider |
| Blackrock Inc | 6.62% | 10,101,715 | $12.53M | Institution |
| Adam Morgan | 5.78% | 8,823,067 | $10.94M | Insider |
| Vanguard Group Inc | 5.55% | 8,471,460 | $10.50M | Institution |
| Adage Capital Partners GP LLC | 5.15% | 7,852,000 | $9.74M | Institution |
| Velan Capital Investment Management LP | 4.58% | 6,986,744 | $8.66M | Institution |
| Baker Brothers Life Sciences Capital GP LLC | 3.45% | 5,266,568 | $6.53M | Insider |
HRTX vs Biotech Stocks
Heron Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.